Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.32 |
| ▸ | ADH1C | P00326 | 2/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21457789 | 0.95 | ADH1A (0.32) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL31476907 | 0.95 | ADH1A (0.32) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL9158295 | 0.95 | ADH1A (0.32) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL2653668 | 0.95 | ADH1A (0.32) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL31476927 | 0.95 | ADH1A (0.32) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL11827376 | 0.93 | ADH1A (0.31) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL3180740 | 0.92 | ADH1A (0.33) | ADH1AADH1CADH1BADH4 | |
| SCHEMBL31008449 | 0.92 | LMNA (0.32) | — | |
| SCHEMBL6588160 | 0.90 | — | — | |
| SCHEMBL6761260 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786307-B2 | suchas N-(4(S)-amino-5(S)-hydroxy-2(S)-isopropyl-6-piperidin-1-ylhexyl)-2-(3-methoxypropoxy)benzamide dihydrochloride, used for the treatment of hypertension, cardiovasculr disorders, complications owing to diabetes, vision deffects, hyperaldosteronism, states of anxiety and cognitive disorders | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1756037-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745777-A1 | Amido-aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | CTSD, BACE1, CTSL | ADH1A 19/4885ADH1C 18/4885ADH1B 242/4885 |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | REN, AGTR1, AGTR2 | ADH1A 5/4885ADH1C 6/4885ADH1B 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.